Fabry disease: Updates from the 15th Annual WorldSymposium

Cost: Free

View Offer chevron_right

Details

Fabry disease is characterized by a deficiency of the glycoside hydrolase enzyme alpha galactosidase A, resulting in the accumulation of the glycolipid globotriaosylceramide throughout the body, particularly prominently in the blood vessels.

After completing Fabry disease: Updates from the 15th Annual WorldSymposium, physicians will better be able to:

  • Describe the pathogenesis, clinical presentations, complications, and epidemiology of Fabry disease including updated material presented at the 15th Annual WORLDSymposium
  • Describe principles and problems regarding screening for and diagnosing Fabry disease that can applied to patient cases
  • Describe emerging therapies for Fabry disease based on research presented at the 15th Annual WORLDSymposium
  • Design and implement appropriate therapeutic plans for treatment of Fabry disease based on research presented at the 15th Annual WORLDSymposium

 

Target Audience: cardiologists, nephrologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Fabry disease.

Stay up-to-date

Receive special offers, keep up with MOC requirements and stay informed of the latest offerings in free online CME in your specialty.